Summary
The urokinase plasminogen activator receptor (uPAR) plays a critical role in urokinase-mediated plasminogen activation and thereby in the process leading to invasion and metastasis. Soluble urokinase receptor (suPAR) is released from tumours, and in cancer patients the blood level of soluble receptor is increased. Using an enzyme-linked, immunosorbent assay (ELISA)-specific for the human urokinase receptor, release of soluble receptor was measured in cultures of human breast carcinoma cells, in tumour extracts and in plasma from mice with xenografted human tumours. Soluble human urokinase receptor (shuPAR) was released into culture supernatant during the growth of the human breast cancer cell line MDA-MB-231 BAG, and the level of shuPAR in conditioned medium determined by ELISA was a linear function of both viable cell number and time of incubation. Western blotting showed that the form of shuPAR measured by ELISA in conditioned medium consisted virtually exclusively of the three-domain full-length protein, while uPAR in cell lysates consisted of full-length uPAR as well as the domains (2+3) cleavage product. shuPAR was also released into the plasma of nude mice during growth of MDA-MB-231 BAG, MDA-MB-435 BAG and HCT 116 cells as subcutaneously xenografted tumours. Western blotting demonstrated that the shuPAR released from the xenografted human tumours into plasma consisted of the three-domain full-length protein, despite the finding of some cleaved uPAR in detergent extracts of tumour tissue. The levels of shuPAR determined by ELISA in the plasma of host mice during the growth of xenografted cell lines were highly correlated with tumour volume.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Andreasen, PA, Kjøller, L, Christensen, L & Duffy, MJ (1997). The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1–22.
Baramova, EN, Bajou, K, Remacle, A, Lhoir, C, Krell, HW, Weidle, UH, Nöel, A & Foidart, JM (1997). Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett 405: 157–162.
Behrendt, N, Rønne, E, Ploug, M, Petri, T, Løber, D, Nielsen, LS, Schleuning, WD, Blasi, F, Appella, E & Danø, K (1990). The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem 265: 6453–6460.
Brünner, N, Thompson, EW, Spang-Thomsen, M, Rygaard, J, Danø, K & Zwiebel, JA (1992). lacZ transduced human breast cancer xenografts as an in vivo model for the study of invasion and metastasis. Eur J Cancer 28A: 1989–1995.
Chavakis, T, Kanse, SM, Yutzy, B, Lijnen, HR & Preissner, KT (1998). Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor–urokinase complexes. Blood 91: 2305–2312.
Chomczynski, P & Sacchi, N (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156–159.
Danø, K, Andreasen, PA, Grøndahl-Hansen, J, Kristensen, P, Nielsen, LS & Skriver, L (1985). Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44: 139–266.
Danø, K, Behrendt, N, Brünner, N, Ellis, V, Ploug, M & Pyke, C (1994). The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 8: 189–203.
Deng, G, Curriden, SA, Wang, SJ, Rosenberg, S & Loskutoff, DJ (1996). Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release. J Cell Biol 134: 1563–1571.
Ellis, V, Behrendt, N & Danø, K (1991). Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 266: 12752–12758.
Feinberg, AP & Vogelstein, B (1983). A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 132: 6–13.
Ganesh, S, Sier, CF, Heerding, MM, Griffioen, G, Lamers, CB & Verspaget, HW (1994). Urokinase receptor and colorectal cancer survival. Lancet 344: 401–402.
Ginestra, A, Monea, S, Seghezzi, G, Dolo, V, Nagase, H, Mignatti, P & Vittorelli, ML (1997). Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J Biol Chem 272: 17216–17222.
Grøndahl-Hansen, J, Peters, HA, Van, PW, Look, MP, Pappot, H, Rønne, E, Danø, K, Klijn, JM, Brünner, N & Foekens, JA (1995). Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Can Res, 1079–1087.
He, CS, Wilhelm, SM, Pentland, AP, Marmer, BL, Grant, GA, Eisen, AZ & Goldberg, GI (1989). Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 86: 2632–2636.
Holst-Hansen, C, Johannessen, B, Høyer-Hansen, G, Rømer, J, Ellis, V & Brünner, N (1996). Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis 14: 297–307.
Høyer-Hansen, G, Behrendt, N, Ploug, M, Danø, K & Preissner, KT (1997). The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett 420: 79–85.
Lau, HK & Kim, M (1994). Soluble urokinase receptor from fibrosarcoma HT-1080 cells. Blood Coagul Fibrinolysis 5: 473–478.
Lyons, RM, Gentry, LE, Purchio, AF & Moses, HL (1990). Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol 110: 1361–1367.
Masucci, MT, Pedersen, N & Blasi, F (1991). A soluble, ligand binding mutant of the human urokinase plasminogen activator receptor. J Biol Chem 266: 8655–8658.
Pappot, H, Høyer-Hansen, G, Rønne, E, Hansen, HH, Brünner, N, Danø, K & Grøndahl-Hansen, J (1997). Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. Eur J Cancer 33: 867–872.
Pedersen, N, Schmitt, M, Rønne, E, Nicoletti, MI, Høyer-Hansen, G, Conese, M, Giavazzi, R, Danø, K, Kuhn, W, Jänicke, F & Blasi, F (1993). A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest 92: 2160–2167.
Pedersen, H, Brünner, N, Francis, D, Østerlind, K, Rønne, E, Hansen, HH, Danø, K & Grøndahl-Hansen, J (1994). Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 54: 4671–4675.
Plesner, T, Behrendt, N & Ploug, M (1997). Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells 15: 398–408.
Ploug, M, Rønne, E, Behrendt, N, Jensen, AL, Blasi, F & Danø, K (1991). Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 266: 1926–1933.
Ploug, M, Ellis, V & Danø, K (1994). Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor. Biochemistry 33: 8991–8997.
Ploug, M, Østergaard, S, Hansen, LBL, Holm, A & Danø, K (1998). Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation. Biochemistry 37: 3612–3622.
Ponte, P, Ng, SY, Engel, J, Gunning, P & Kedes, L (1984). Evolutionary conservation in the untranslated regions of actin mRNAs: DNA sequence of a human beta-actin cDNA. Nucleic Acids Res 12: 1687–1696.
Pyke, C, Kristensen, P, Ralfkiaer, E, Grøndahl-Hansen, J, Eriksen, J, Blasi, F & Danø, K (1991). Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 138: 1059–1067.
Pyke, C, Graem, N, Ralfkiaer, E, Rømer, J, Høyer-Hansen, G, Brünner, N & Danø, K (1993). Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 15: 1911–1915.
Resnati, M, Guttinger, M, Valcamonica, S, Sidenius, N, Blasi, F & Fazioli, F (1996). Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 15: 1572–1582.
Roldan, AL, Cubellis, MV, Masucci, MT, Behrendt, N, Lund, LR, Danø, K, Appella, E & Blasi, F (1990). Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 9: 467–474.
Rømer, J, Pyke, C, Lund, LR, Eriksen, J, Kristensen, P, Rønne, E, Høyer-Hansen, G, Danø, K & Brünner, N (1994). Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion. Int J Cancer 57: 553–560.
Rønne, E, Behrendt, N, Ploug, M, Nielsen, HJ, Wollisch, E, Weidle, U, Danø, K & Høyer-Hansen, G (1994). Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked linked immunosorbent assay. J Immunol Methods 167: 91–101.
Rønne, E, Høyer-Hansen, G, Brünner, N, Pedersen, H, Rank, F, Osborne, CK, Clark, GM, Danø, K & Grøndahl-Hansen, J (1995a). Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat 33: 199–207.
Rønne, E, Pappot, H, Grøndahl-Hansen, J, Høyer-Hansen, G, Plesner, T, Hansen, NE & Danø, K (1995b). The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 89: 576–581.
Shapiro, RL, Duquette, JG, Roses, DF, Nunes, I, Harris, MN, Kamino, H, Wilson, EL & Rifkin, DB (1996). Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice – cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res 56: 3597–3604.
Sier, CFM, Stephens, RW, Bizik, J, Mariani, A, Bassan, M, Pedersen, N, Frigerio, L, Ferrari, A, Danø, K, Brünner, N & Blasi, F (1998). The level of urokinase plasminogen activator receptor (uPAR) is increased in serum of ovarian cancer patients. Cancer Res 58: 1843–1849.
Solberg, H, Rømer, J, Brünner, N, Holm, A, Sidenius, N, Danø, K & Høyer-Hansen, G (1994). A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int J Cancer 58: 877–881.
Stephens, RW, Pedersen, AN, Nielsen, HJ, Hamers, MJ, Høyer-Hansen, G, Rønne, E, Dybkjær, E, Danø, K & Brünner, N (1997). ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 43: 1868–1876.
Stephens, RW, Nielsen, HJ, Christensen, IJ, Thorlacius-Ussing, O, Sørensen, S, Danø, K & Brünner, N (1999). Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 91: 869–874.
Wilhelm, O, Weidle, U, Hohl, S, Rettenberger, P, Schmitt, M & Graeff, H (1994). Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett 337: 131–134.
Wohn, KD, Kanse, SM, Deutsch, V, Schmidt, T, Eldor, A & Preissner, KT (1997). The urokinase-receptor (CD87) is expressed in cells of the megakaryoblastic lineage. Thromb Haemost 77: 540–547.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Holst-Hansen, C., Hamers, M., Johannessen, B. et al. Soluble urokinase receptor released from human carcinoma cells: A plasma parameter for xenograft tumour studies. Br J Cancer 81, 203–211 (1999). https://doi.org/10.1038/sj.bjc.6690678
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690678
Keywords
This article is cited by
-
Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients
British Journal of Cancer (2010)
-
CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review
Leukemia (2004)